Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
IRVINE, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points...
-
Transaction includes proprietary IP and technology for blood-based immune therapy monitoring and for transplant rejection testing Novel, patented copy number index (CNI) therapy monitoring test...
-
Data shows broad adoption and real-world clinical utility of its DetermaRx™ test for early-stage lung cancer IRVINE, Calif., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE...
-
Offering Led by Current Shareholder and Healthcare Investor, Pura Vida Investments, Substantially Increasing Its Holdings Further Strengthens Balance Sheet to Support Ongoing Commercial and...
-
IRVINE, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points...
-
IRVINE, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points...
-
Aligns Oncocyte with one of China’s fastest growing NGS-based cancer therapy selection companies; China is considered to be the world’s largest early-stage lung cancer market Exclusive agreement...
-
IRVINE, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points...
-
IRVINE, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points...
-
Data demonstrate that DetermaIO™ can be run successfully using limited tissue from small biopsy specimens, overcoming the significant challenges associated with tissue availability for molecular...